Product Information

OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.7432 per EA under NDC 00093500556. Its NADAC has been published 488 times since Apr 19, 2017.

FDA first approved this application on Nov 3, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5

Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide
$0.7432per EA

Strength

5; 12.5; 20 mg/1; mg/1; mg/1

NDC

00093500556

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA202491

FDA Approved

11/3/2016

TE Code

AB

On Market Since

11/14/2016

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A Inhibitors
Dihydropyridine Calcium Channel Blocker
Dihydropyridines
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 has been published 488 times since Apr 19, 2017, and over the history we have for it it has declined 71.1%. The table below summarizes its recorded NADAC range and movement.

Current price$0.7432 per EA
All-time high$2.7845 (Dec 13, 2017)
All-time low$0.7432 (Aug 19, 2026)
52-week high$0.9630
52-week low$0.7432
Median price$1.3821
Average price$1.4817
Largest weekly change+49.6% (May 22, 2019)
Weeks tracked488
Tracking sinceApr 19, 2017

Price History

1W

-3.9%

1M

-3.9%

3M

-14.3%

6M

-20.2%

1Y

-22.8%

3Y

-24.9%

5Y

-42.6%

All

-71.1%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5?

The current National Average Drug Acquisition Cost (NADAC) for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5, manufactured by Teva Pharmaceuticals USA Inc., is $0.7432 per EA (NDC 00093500556), effective Aug 19, 2026.

How has the price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 changed over time?

Over the history we have for it, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 has declined 71.1%. It has been tracked across 488 weekly CMS publications since Apr 19, 2017.

What are the highest and lowest recorded NADAC prices for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5?

Since Apr 19, 2017, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 has ranged from a low of $0.7432 (Aug 19, 2026) to a high of $2.7845 (Dec 13, 2017), with a median of $1.3821 per EA.

Are there cheaper alternatives to OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5?

No other NADAC-published product currently shares the active ingredient and strength of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5?

OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 (NDC 00093500556) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.